Medicare denying Wegovy\u00ae is one of the most common and most fixable insurance problems in 2026. The denial usually isn’t personal and it usually isn’t final. Whether your appeal can succeed depends almost entirely on which clinical pathway your prescription went through and what documentation supports it.<\/p>\n
Here’s the core issue. Medicare Part D is barred by federal law (the 2003 Medicare Modernization Act) from covering medications used for “anorexia, weight loss, or weight gain.” That single sentence has blocked Medicare coverage of obesity drugs for two decades. But in March 2024, CMS issued guidance that opened a narrow door: Wegovy is coverable for cardiovascular risk reduction in patients with established CVD and a BMI of 27 or higher, after the SELECT trial (Lincoff et al. 2023 NEJM) showed 20% reduction in major adverse cardiovascular events.<\/p>\n
So if your Wegovy was prescribed for weight loss alone, Medicare’s denial is going to stick. If it was prescribed for cardiovascular risk reduction in a patient with prior MI, stroke, or PAD, the denial is almost certainly appealable and usually winnable.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The most common reason is that Wegovy was submitted with an obesity diagnosis code (E66.x) rather than a cardiovascular indication.<\/strong> Medicare Part D plans are required by law to exclude weight-loss-only coverage, so any claim that reads as “weight management” without a cardiovascular qualifier gets auto-denied at the PBM adjudication step.<\/p>\n Quick Answer: Medicare Part D legally cannot cover Wegovy for weight loss alone, but can cover it for cardiovascular risk reduction in patients with established CVD and BMI of 27+<\/p>\n Other common denial reasons include missing documentation of established cardiovascular disease, lack of recent BMI measurement on file, prescriber not being enrolled in Medicare, step therapy requirements not met, and quantity limit exceedances. About 70% of initial Medicare Wegovy denials in 2025 were due to indication coding rather than true medical necessity disputes.<\/p>\n Read the denial letter (called a coverage determination notice) and find the specific reason code. The denial reason determines which appeal path will actually work.<\/p>\n Yes, in the right clinical scenario.<\/strong> In March 2024, CMS issued a memo allowing Medicare Part D plans to cover Wegovy for cardiovascular risk reduction in patients with established cardiovascular disease (defined as prior MI, prior stroke, or symptomatic peripheral artery disease) and BMI of 27 kg\/m\u00b2 or higher. Coverage requires the prescription to be specifically for CV indication, not weight loss.<\/p>\n This pathway opened after the SELECT trial enrolled 17,604 patients with established CVD and BMI 27+, and showed that semaglutide 2.4 mg weekly reduced the composite of cardiovascular death, nonfatal MI, and nonfatal stroke by 20% compared to placebo over an average 33-month follow-up. The FDA approved the new indication in March 2024.<\/p>\n Your prescription has to be coded with ICD-10 codes for the CV condition (I25.2 for prior MI, I63.x for prior stroke, I73.9 for PAD) plus Z68.27+ for BMI 27 or higher. If the prescriber writes “for weight loss” or “for obesity” in the notes, the claim will get denied regardless of the diagnosis codes.<\/p>\n There are five levels of Medicare Part D appeals.<\/strong> Level 1 is redetermination by your Part D plan, which must be filed within 60 days of the denial. Level 2 is reconsideration by an independent review entity (IRE) within 60 days of the level 1 denial. Level 3 is administrative law judge hearing for claims over the AIC threshold (around $190 in 2026). Level 4 is the Medicare Appeals Council, and level 5 is federal district court.<\/p>\n For Wegovy denials, most cases are won or lost at levels 1 or 2. Standard redetermination decisions come within 7 days, expedited within 72 hours. Reconsideration by the IRE takes 14 days standard or 72 hours expedited. Request expedited review if waiting could seriously jeopardize your health.<\/p>\n File the appeal in writing, or by phone if your plan accepts phone appeals. Use the form on your denial letter or download CMS Form 1696 from cms.gov. Don’t skip the deadline. Late appeals are dismissed without consideration.<\/p>\n The strongest appeals include four things.<\/strong> A letter of medical necessity from the prescriber citing FDA labeling and SELECT trial data. Chart documentation of established cardiovascular disease (cath reports, MRI\/CT showing prior stroke, vascular imaging for PAD). BMI documentation showing the patient meets the 27+ threshold. And documentation of any prior weight-management or cardiovascular therapies tried.<\/p>\n The letter of medical necessity should explicitly state that the prescription is for cardiovascular risk reduction under the FDA-approved indication, not for weight loss. Cite Lincoff et al. 2023 NEJM by name. State the patient’s specific CVD history with dates. Quote the relevant section of the patient’s chart. A vague letter that just says “patient needs this medication” almost never wins.<\/p>\n A 2024 analysis from the Center for Medicare Advocacy found that appeals with prescriber letters of medical necessity were overturned 47% of the time, compared to 18% for appeals without them.<\/p>\n You move to level 2, the independent review entity (IRE).<\/strong> The IRE is a contractor outside your plan, so they look at the case fresh. File the level 2 appeal within 60 days of the level 1 denial. The IRE has 14 days to decide a standard appeal or 72 hours for expedited.<\/p>\n At level 2, you can submit additional evidence that wasn’t in the level 1 appeal. Common additions include peer-reviewed literature on GLP-1 cardiovascular benefit, additional chart documentation, and second-opinion letters from cardiologists. The IRE overturn rate on GLP-1 cases in 2024 was approximately 38%, according to data from the Office of Medicare Hearings and Appeals.<\/p>\n If level 2 fails and your claim exceeds the dollar threshold, you can request an administrative law judge hearing. ALJ hearings are conducted by phone or video and decided within 90 days. ALJ overturn rates for Medicare appeals run around 45% across all drug categories.<\/p>\n Key Takeaway: Standard appeals must be filed within 60 days of the denial; expedited appeals are decided within 72 hours<\/p>\n Wegovy itself is not FDA-approved for type 2 diabetes.<\/strong> Ozempic\u00ae is the diabetes formulation of semaglutide. If you have diabetes, your Part D plan should cover Ozempic with PA, not Wegovy. Submitting a Wegovy claim with a diabetes diagnosis will be denied as off-label.<\/p>\n For obstructive sleep apnea, tirzepatide (Zepbound\u00ae) received FDA approval in December 2024 after the SURMOUNT-OSA trial showed substantial AHI reduction in patients with moderate-to-severe OSA and obesity. Semaglutide does not have an OSA indication. Medicare’s coverage for tirzepatide-OSA is still being finalized in 2026, and some Part D plans cover it under the OSA medical necessity pathway while others don’t.<\/p>\n If your real clinical need is diabetes or sleep apnea, switching to the correctly-indicated drug usually resolves the coverage problem.<\/p>\n You probably can’t get Medicare to cover Wegovy.<\/strong> The CV indication is the only opening Medicare has. Without prior MI, prior stroke, or symptomatic PAD, there’s no legal pathway for Part D coverage in 2026.<\/p>\n The Treat and Reduce Obesity Act (TROA) has been introduced in every Congress since 2013 and would amend the Medicare Modernization Act to allow obesity drug coverage. As of mid-2026 it still hasn’t passed. CMS has also proposed expanding the CV indication to primary prevention (no prior event) in patients with very high cardiovascular risk, but this proposal is in rulemaking and not active policy.<\/p>\n Your realistic options are the manufacturer cash program (NovoCare sells Wegovy vials for around $499\/month at all doses), compounded semaglutide through a licensed telehealth provider ($200-400\/month), or pursuing a Medicare Advantage plan that includes supplemental obesity drug benefits (a small but growing number do, especially in Special Needs Plans).<\/p>\n Medicare Advantage Part D plans operate under the same federal restrictions as standalone Part D plans for the obesity indication.<\/strong> They can cover Wegovy for the CV indication. Some MA plans (especially D-SNPs and chronic condition SNPs) offer supplemental benefits that include limited obesity drug coverage, but these are exceptions.<\/p>\n If you’re shopping plans during AEP (October 15 to December 7), check the plan’s drug list and any supplemental obesity benefits. Plans change formularies annually, so a plan that covered Wegovy in 2025 might exclude it in 2026 or vice versa. The Medicare Plan Finder at medicare.gov shows current formulary status.<\/p>\n Yes, but you’ll pay cash.<\/strong> Medicare doesn’t reimburse compounded medications since they aren’t FDA-approved drugs. Licensed telehealth providers like TrimRx prescribe compounded semaglutide through 503A pharmacies for patients who don’t have insurance coverage or whose insurance excludes weight-management GLP-1s. Typical pricing is $200-400 per month.<\/p>\n The FDA removed semaglutide from its drug shortage list in February 2025, which restricted 503B outsourcing facilities from mass-compounding it. 503A pharmacies can still compound personalized formulations under a state-licensed physician’s prescription for individual patients with documented clinical need.<\/p>\n A free assessment quiz from a licensed provider can determine whether compounded therapy is clinically appropriate given your full medical picture, including any cardiovascular history that might still warrant pursuing Wegovy through the CV pathway.<\/p>\n Bottom line: If appeals fail, manufacturer cash programs ($499\/month NovoCare) and compounded semaglutide ($200-400\/month) are realistic alternatives<\/p>\n Standard level 1 redetermination is 7 days. Expedited is 72 hours. Level 2 IRE is 14 days standard or 72 hours expedited. If you’re escalating to administrative law judge, expect 90 days.<\/p>\n Medicare Part D plans don’t offer formal peer-to-peer like commercial plans, but the prescriber can request a coverage determination phone consultation with the plan’s medical director before filing a written appeal. This often resolves the denial faster than a full appeal.<\/p>\n No. Ozempic is FDA-approved for type 2 diabetes only. Medicare covers Ozempic for diabetes with PA. Off-label prescriptions for weight loss are denied. Wegovy is the same molecule (semaglutide) at higher doses for weight or cardiovascular use.<\/p>\n BMI of 27 kg\/m\u00b2 or higher, plus established cardiovascular disease (prior MI, stroke, or symptomatic PAD). BMI alone, even at 40+, doesn’t trigger Medicare coverage without the CV qualifier.<\/p>\n You can appeal yourself. Most Part D appeals are filed by patients and prescribers without legal representation. A Medicare patient advocate (free through SHIP, the State Health Insurance Assistance Program) can help draft the appeal at no cost.<\/p>\n If you’re dual-eligible (Medicare and Medicaid), Medicaid is your secondary payer for prescriptions. Some state Medicaid programs cover Wegovy for obesity (California, Indiana, others), and may cover it even when Medicare denies. Check your state Medicaid PDL.<\/p>\n Retail cash price is around $1,350 per month at most pharmacies. The NovoCare direct cash program sells Wegovy vials for around $499 per month at any dose, no insurance required. GoodRx and similar tools usually don’t beat NovoCare’s pricing for cash-pay patients.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Medicare denying Wegovy is one of the most common and most fixable insurance problems in 2026.<\/p>\n","protected":false},"author":11,"featured_media":93128,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"What to Do When Medicare Denies Wegovy: Appeal Strategy","_yoast_wpseo_metadesc":"Medicare denying Wegovy is one of the most common and most fixable insurance problems in 2026.","_yoast_wpseo_focuskw":"medicare denies wegovy","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[13],"tags":[23,30,55],"class_list":["post-90201","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-wegovy","tag-cost-coverage","tag-insurance","tag-wegovy"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90201"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90201\/revisions"}],"predecessor-version":[{"id":91652,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90201\/revisions\/91652"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93128"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Can Medicare Cover Wegovy for Heart Disease?<\/h2>\n
How Do I File a Medicare Part D Appeal?<\/h2>\n
What Documentation Does My Appeal Need?<\/h2>\n
What If My Appeal Is Denied at Level 1?<\/h2>\n
What About Wegovy for Diabetes or Sleep Apnea?<\/h2>\n
What If I Don’t Have Established Cardiovascular Disease?<\/h2>\n
Does Medicare Advantage Cover Wegovy Differently Than Original Medicare?<\/h2>\n
Can I Use Compounded Semaglutide If Medicare Won’t Cover Wegovy?<\/h2>\n
FAQ<\/h2>\n
How Long Does a Medicare Wegovy Appeal Take?<\/h3>\n
Can My Doctor Request a Peer-to-peer Review with Medicare?<\/h3>\n
Does Medicare Cover Ozempic for Weight Loss?<\/h3>\n
What’s the BMI Threshold for Medicare to Cover Wegovy?<\/h3>\n
Can I Appeal a Medicare Denial Myself or Do I Need a Lawyer?<\/h3>\n
Does Medicaid Cover Wegovy If Medicare Denies It?<\/h3>\n
How Much Does Wegovy Cost Without Insurance?<\/h3>\n